Lexicon Pharmaceuticals Inc

The stock has lost intermediate EMA control with 9/20 EMAs crossing below the 50-day SMA and price closing decisively underneath, indicating structural repair to the downside. Price trading beneath converged EMAs with flat to downward tilt and neutral momentum signals confirms a bearish medium-term bias. Short-term timing is unfavorable for new longs, and the tradable side is bearish. Engagement should occur on rallies into the $2.30–$2.35 resistance zone at the EMA cluster, using rejection setups.

• ↑JACC: Heart Failure study shows sotagliflozin efficacy at low systolic BP
• ↑Received $10M milestone payment from Novo Nordisk for LX9851
• ↓Negative earnings yield (-0.11) and weak profitability raise concerns